Entrada Therapeutics, Inc.
NGM: TRDALive Quote
📈 ZcoreAI Score
Our AI model analyzes Entrada Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get TRDA Z-Score →About Entrada Therapeutics, Inc.
Healthcare
Biotechnology
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
📊 Fundamental Analysis
Entrada Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported -96.5% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -39.1%, which indicates that capital utilization is currently under pressure.
At a current price of $13.50, TRDA currently trades near the top of its 52-week range (91%) (Range: $4.93 - $14.36).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$516.84M
Trailing P/E
--
Forward P/E
-3.92
Beta (5Y)
-0.15
52W High
$14.36
52W Low
$4.93
Avg Volume
224K
Day High
Day Low